AMRX / Amneal Pharmaceuticals (AMRX) Beats Q4 Earnings and Revenue Estimates

Amneal (AMRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the sto more_horizontal

Here is how Amneal Pharmaceuticals (AMRX) and KalVista Pharmaceuticals, Inc. (KALV) have performed compared to their sector so far this year. more_horizontal

Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat i more_horizontal

Amneal (AMRX) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gai more_horizontal

Investors often rely on stock market news to stay abreast of everything, ranging from low-cost penny stocks to industry giants such as Apple or Tesla. more_horizontal

Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of $0.10 per share. This compa more_horizontal

Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat i more_horizontal

Amneal has more than 270 products. On Tuesday, the company launched a generic for Xyrem to treat excessive daytime sleepiness. more_horizontal